Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alosetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 2/20 | 0.74 |
| ▸ | HTR2A | P28223 | 5/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.74 |
| ▸ | HTR2B | P41595 | 4/20 | 0.74 |
| ▸ | HTR2C | P28335 | 4/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.74 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.74 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.74 |
| ▸ | CASP6 | P55212 | 1/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.40 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.40 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.40 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.40 |
| ▸ | HTR3B | O95264 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alosetron SCHEMBL311317 | 0.99 | CASP6 (0.74) | HTR2AKCNH2HTR2BHTR2CCYP3A4 | |
| Alosetron SCHEMBL7371660 | 0.99 | CASP6 (0.74) | HTR2AKCNH2HTR2BHTR2CCYP3A4 | |
| Alosetron SCHEMBL2229995 | 0.92 | KCNH2 (0.65) | HTR2AKCNH2HTR2BHTR2CCYP3A4 | |
| SCHEMBL20027463 | 0.88 | KCNH2 (0.57) | HTR2AKCNH2HTR2BHTR2CCYP3A4 | |
| SCHEMBL20022665 | 0.87 | HTR2A (0.56) | HTR2AKCNH2HTR2BHTR2CCYP3A4 | |
| Alosetron SCHEMBL631 | 0.85 | KCNH2 (1.00) | HTR2AKCNH2HTR2BHTR2CCYP3A4 | |
| Alosetron SCHEMBL29377019 | 0.85 | KCNH2 (1.00) | HTR2AKCNH2HTR2BHTR2CCYP3A4 | |
| Alosetron SCHEMBL29387635 | 0.84 | CASP6 (1.00) | HTR2AKCNH2HTR2BHTR2CCYP3A4 | |
| Alosetron SCHEMBL806 | 0.84 | CASP6 (1.00) | HTR2AKCNH2HTR2BHTR2CCYP3A4 | |
| SCHEMBL3321223 | 0.84 | KCNH2 (0.54) | HTR2AKCNH2HTR2BHTR2CCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5699 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144776-A1 | COMBINATION THERAPY FOR A DOPAMINE AGONIST | ALTO NEUROSCIENCE, INC. (US) | 2026-05-28 | — | — | US | claimed |
| EP-4725483-A1 | COMBINATION COMPRISING AT LEAST ONE 5-HT2A RECEPTOR ANTAGONIST AND AT LEAST ONE 5-HT3 RECEPTOR ANTAGONIST AND ITS MEDICAL USE | Université de Bordeaux (FR) | 2026-04-15 | — | — | EP | claimed |
| EP-4705511-A1 | DNA METHYLATION-BASED ALGORITHM TO DIAGNOSE IRRITABLE BOWEL SYNDROME AND OTHER GI CONDITIONS | The Regents of the University of California (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4683627-A1 | AMELIORATION OF DRUG-DRUG INTERACTIONS | Ontrack Therapeutics Limited (GB) | 2026-01-28 | — | — | EP | claimed |
| EP-4658240-A2 | PHARMACEUTICAL COMPOSITIONS FOR NASAL DELIVERY | Therakind Limited (GB) | 2025-12-10 | — | — | EP | claimed |
| US-20250255781-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-08-14 | — | — | US | claimed |
| CN-120189416-A | Method for treating bile acid diarrhea | 加利福尼亚大学董事会 | 2025-06-24 | — | — | CN | claimed |
| US-20250177418-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. | 2025-06-05 | — | — | US | claimed |
| US-20250170149-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | claimed |
| US-20250170148-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | claimed |
| CN-1281357-A | Medicaments | GLAXO GROUP LTD (GB) | 2001-01-24 | — | — | CN | claimed |
| WO-2000076500-A2 | COMPOUND FOR USE AS A MEDICAMENT FOR TREATMENT OF DISORDERS INVOLVING BRONCHOCONTRACTION | RESPIRATORIUS AB (SE) | 2000-12-21 | — | — | WO | claimed |
| WO-2000048597-A1 | SYSTEMIC USE OF 5-HT3 RECEPTOR ANTAGONISTS AGAINST RHEUMATIC INFLAMMATORY PROCESSES | NOVARTIS AG (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-2000048581-A2 | USE OF 5-HT3 RECEPTOR ANTAGONISTS FOR TREATING MUSCULOESKELETAL DISEASES | NOVARTIS AG (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-1021174-A2 | MEDICAMENTS | GLAXO GROUP LIMITED (GB) | 2000-07-26 | — | — | EP | claimed |
| WO-2000037073-A1 | USE OF 5HT3-RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CHRONIC FATIGUE SYNDROME | NOVARTIS PHARMA GMBH (DE) | 2000-06-29 | — | — | WO | claimed |
| WO-1999017755-A2 | MEDICAMENTS | GLAXO GROUP LIMITED (GB) | 1999-04-15 | — | — | WO | claimed |
| CN-1201390-A | 5-HT3 receptor antagonists for treating dyskinesia | GLAXO WELLCOME INC (GB) | 1998-12-09 | — | — | CN | claimed |
| EP-0851756-A1 | 5-HT 3? RECEPTOR ANTAGONISTS FOR DYSKINESIA | GLAXO GROUP LIMITED (GB) | 1998-07-08 | — | — | EP | claimed |
| WO-1997010823-A1 | 5-HT3 RECEPTOR ANTAGONISTS FOR DYSKINESIA | GLAXO GROUP LIMITED (GB) | 1997-03-27 | — | — | WO | claimed |